vTv Therapeutics (VTVT) Retained Earnings (2015 - 2026)

vTv Therapeutics has disclosed Retained Earnings across 12 years of filings, most recently posting -$315.6 million for Q2 2026.

• In Q2 2026, Retained Earnings fell 1.52% year-over-year to -$315.6 million; the TTM figure through Jun 2026 stood at -$315.6 million (down 1.52% YoY), while the FY2025 annual figure was -$326.7 million, down 9.0% from the prior year.
• Retained Earnings came in at -$315.6 million for Q2 2026 at vTv Therapeutics, down from -$302.6 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$247.7 million in Q1 2022 to a low of -$326.7 million in Q4 2025.
• Average Retained Earnings over 5 years is -$289.1 million, with a median of -$288.7 million recorded in 2024.
• Year-over-year, Retained Earnings gained 9.84% in 2022 and dropped 10.86% in 2023.
• Over 5 years, Retained Earnings stood at -$265.5 million in 2022, then retreated by 5.84% to -$281.0 million in 2023, then decreased by 6.65% to -$299.7 million in 2024, then slipped by 9.0% to -$326.7 million in 2025, then advanced by 3.39% to -$315.6 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$315.6 million in Q2 2026, -$302.6 million in Q1 2026, and -$326.7 million in Q4 2025.